NRIX vs. NUVL, GRFS, VKTX, AXSM, TGTX, KRYS, OGN, SRRK, ADMA, and ALVO
Should you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Nuvalent (NUVL), Grifols (GRFS), Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), Krystal Biotech (KRYS), Organon & Co. (OGN), Scholar Rock (SRRK), ADMA Biologics (ADMA), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.
Nurix Therapeutics vs.
Nuvalent (NASDAQ:NUVL) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
Nuvalent has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500.
Nurix Therapeutics received 32 more outperform votes than Nuvalent when rated by MarketBeat users. Likewise, 78.95% of users gave Nurix Therapeutics an outperform vote while only 78.18% of users gave Nuvalent an outperform vote.
97.3% of Nuvalent shares are owned by institutional investors. 12.5% of Nuvalent shares are owned by company insiders. Comparatively, 7.2% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Nuvalent has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -313.65%. Nuvalent's return on equity of -28.63% beat Nurix Therapeutics' return on equity.
Nuvalent currently has a consensus price target of $112.36, suggesting a potential upside of 48.16%. Nurix Therapeutics has a consensus price target of $30.35, suggesting a potential upside of 58.58%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than Nuvalent.
In the previous week, Nuvalent had 9 more articles in the media than Nurix Therapeutics. MarketBeat recorded 15 mentions for Nuvalent and 6 mentions for Nurix Therapeutics. Nuvalent's average media sentiment score of 0.49 beat Nurix Therapeutics' score of 0.23 indicating that Nuvalent is being referred to more favorably in the media.
Nuvalent has higher earnings, but lower revenue than Nurix Therapeutics. Nuvalent is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Nuvalent and Nurix Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Nurix Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nurix Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NRIX) was last updated on 1/18/2025 by MarketBeat.com Staff
